Detalhe da pesquisa
1.
Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 388(2): 117-127, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331190
2.
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
J Am Soc Nephrol
; 35(2): 202-215, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082486
3.
Baseline urinary osteopontin levels are associated with the improvement of metabolic syndrome.
Nutr Metab Cardiovasc Dis
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38664124
4.
Albuminuria improves R2CHA2DS2-VASc score in predicting mortality in high cardiovascular risk population.
Nutr Metab Cardiovasc Dis
; 33(8): 1591-1598, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37263913
5.
Among biomarkers of neutrophil activity, matrix metalloproteinases 8 independently predicts remission of metabolic syndrome.
Nutr Metab Cardiovasc Dis
; 33(1): 185-193, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411219
6.
Hyperuricemia increases the risk of cardiovascular mortality associated with very high HdL-cholesterol level.
Nutr Metab Cardiovasc Dis
; 33(2): 323-330, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642602
7.
Role of Uric Acid in Vascular Remodeling: Cytoskeleton Changes and Migration in VSMCs.
Int J Mol Sci
; 24(3)2023 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36769281
8.
Non-Haemodynamic Mechanisms Underlying Hypertension-Associated Damage in Target Kidney Components.
Int J Mol Sci
; 24(11)2023 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37298378
9.
CHA2DS2-VASc and R2CHA2DS2-VASc scores predict mortality in high cardiovascular risk population.
Eur J Clin Invest
; 52(11): e13830, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35778894
10.
Low GFR amplifies the association between coronary three-vessel disease and all-cause mortality.
Nutr Metab Cardiovasc Dis
; 32(2): 402-409, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34893408
11.
Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project.
Nutr Metab Cardiovasc Dis
; 32(5): 1245-1252, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35282979
12.
Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study.
Eur J Clin Invest
; 51(3): e13403, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918277
13.
SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits.
Int J Mol Sci
; 22(9)2021 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33922865
14.
Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.
Curr Hypertens Rep
; 22(12): 102, 2020 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33128170
15.
Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age.
Int J Mol Sci
; 21(12)2020 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32599713
16.
Uric acid and angiotensin II additively promote inflammation and oxidative stress in human proximal tubule cells by activation of toll-like receptor 4.
J Cell Physiol
; 234(7): 10868-10876, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30536556
17.
Baseline hs-CRP predicts hypertension remission in metabolic syndrome.
Eur J Clin Invest
; 49(8): e13128, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31091356
18.
GLP-1 Receptor Agonists and Kidney Protection.
Medicina (Kaunas)
; 55(6)2019 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31159279
19.
Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach.
Medicina (Kaunas)
; 55(7)2019 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31315312
20.
Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes.
Kidney Blood Press Res
; 43(2): 422-438, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29698970